LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

Strona główna・Stock List・AnaptysBio Inc

AnaptysBio Inc

Closed

SectorHealthcare

56.85 -2.44

Buy Sell

Overview

Share price change

24h

Current

Min

56.56

Max

58.85

Key metrics
By Trading Economics
Income	-102M -53M
Sales	-83M 26M
EPS	-1.843
Profit margin	-206.934
Employees	104
EBITDA	-102M -34M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+39.54% upside

Dividends
By Dow Jones
Next Earnings	4 sie 2026

Market Stats
By TradingEconomics
Market Cap	-272M 1.7B
Previous open	59.29
Previous close	56.85

News Sentiment

By Acuity

72%

28%

305 / 344 Ranking in Healthcare

AnaptysBio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

28 maj 2026, 22:47 UTC

Earnings

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 maj 2026, 20:45 UTC

Earnings

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 maj 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 maj 2026, 23:39 UTC

Market Talk

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 maj 2026, 23:31 UTC

Market Talk

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 maj 2026, 23:17 UTC

Market Talk

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 maj 2026, 23:02 UTC

Market Talk

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 maj 2026, 22:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 maj 2026, 22:41 UTC

Market Talk

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 maj 2026, 22:37 UTC

Market Talk

Acquisitions, Mergers, Takeovers

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 maj 2026, 22:04 UTC

Acquisitions, Mergers, Takeovers

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 maj 2026, 22:04 UTC

Acquisitions, Mergers, Takeovers

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 maj 2026, 21:12 UTC

Earnings

Acquisitions, Mergers, Takeovers

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 maj 2026, 21:00 UTC

Earnings

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 maj 2026, 20:57 UTC

Earnings

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 maj 2026, 20:55 UTC

Earnings

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 maj 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

28 maj 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28 maj 2026, 20:48 UTC

Hot Stocks

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 maj 2026, 20:34 UTC

Earnings

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 maj 2026, 20:31 UTC

Earnings

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 maj 2026, 20:28 UTC

Earnings

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 maj 2026, 20:26 UTC

Earnings

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 maj 2026, 20:20 UTC

Earnings

Costco 3Q Membership Fees $1.37B

28 maj 2026, 20:20 UTC

Earnings

Costco 3Q Net Sales $69.15B

28 maj 2026, 20:19 UTC

Earnings

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 maj 2026, 20:19 UTC

Earnings

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 maj 2026, 20:17 UTC

Earnings

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 maj 2026, 20:17 UTC

Earnings

Costco 3Q Same-Store Sales Up 9.8% >COST

Peer Comparison

Price change

AnaptysBio Inc Forecast

Price Target

By TipRanks

39.54% upside

12 Months Forecast

Average 80.5 USD 39.54%

High 140 USD

Low 50 USD

Based on 11 Wall Street analysts offering 12 month price targets forAnaptysBio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to AnaptysBio Inc - Dist in the past 3 months.

Sentiment

By Acuity

305 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.